Daratumumab, bortezomib/thalidomide/dexamethasone (D-VTd) and DARA maintenance shows benefit in transplant-eligible NDMM

Revolutionising myeloma treatment through immune profiling

Treating relapsed multiple myeloma outside of use of T-cell redirected therapies

ESMO and WCLC: Latest developments in EGFR mutated NSCLC

Cabozantinib demonstrates significant improvement in PFS by BICR in advanced neuroendocrine tumours

Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients

Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies

Comment: Trial updates from GALAXIES Lung-201 and RELATIVITY-104 in NSCLC

Amivantamab-lazertinib continue to show benefit as a first-line standard-of-care for EGFR-mutated advanced NSCLC